Preventable Hospitalizations ID'd in Pediatric Medical Complexity

This article originally appeared here.
Share this content:
Preventable Hospitalizations ID'd in Pediatric Medical Complexity
Preventable Hospitalizations ID'd in Pediatric Medical Complexity

(HealthDay News) -- A review published online Nov. 10 in Pediatrics identifies the characteristics of preventable hospitalizations for children with medical complexity (CMC), and offers strategies for the prevention of these hospitalizations.

Ryan J. Coller, M.D., M.P.H., from the University of Wisconsin in Madison, and colleagues conducted a systematic review involving 13 observational studies to characterize potentially preventable hospitalizations in CMC. The authors also reviewed four experimental studies that assessed the efficacy of interventions to reduce CMCs.

Preventable hospitalizations were measured by ambulatory care sensitive conditions, readmission, or investigator-defined criteria. The researchers found that the rates of preventable hospitalizations were higher for postsurgical patients, for those with neurologic disorders and medical devices, and among those with public insurance and nonwhite race/ethnicity. Additional risks included passive smoke exposure, nonadherence to medications, and lack of follow-up after discharge. In more complex patients, hospitalizations for ambulatory care sensitive conditions were less common. Fewer preventable hospitalizations were seen among patients receiving home visits, care coordination, chronic care management, and continuity across settings.

"Reductions in hospital use among CMC might be possible," the authors write. "Strategies should target primary drivers of preventable hospitalizations."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths